Form 10-Q · Quarterly report
Zimmer Biomet 10-Q, filed Nov 4, 2026
- Filed
- CIK
- 0001136869
- Accession no.
- 0001193125-26-447203
Summary
Zimmer Biomet reported net sales of $2.06 billion for the quarter ended September 30, 2026, up 3.1% from a year earlier, and $6.33 billion for the nine months, up 5.7%. Knee sales fell 3.1% in the quarter amid a U.S. sales-force transition and a China distributor transition, while Hips rose 6.0% and S.E.T. rose 6.8%; global selling prices declined 0.7% and operating profit was 14.9% of net sales versus 17.6% a year earlier.
Key points
- Third-quarter U.S. net sales rose 3.6% to $1.21 billion and international net sales rose 2.4% to $857.2 million.
- The Paragon 28 acquisition contributed 1.5 percentage points to nine-month volume growth and 5.8 percentage points to nine-month S.E.T. sales growth.
- Technology & Data, Bone Cement and Surgical net sales grew 11.9% in the quarter and 16.0% over nine months on strong ROSA Robot and bone cement sales.
- Zimmer Biomet initiated a Manufacturing Network Optimization Plan in September 2026, alongside previously announced restructuring programs, recognizing $14.4 million in quarterly and $50.5 million in nine-month expenses.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Results of Operations We review sales by two geographies, the United States and International, and by the following product categories: Knees; Hips; S.E.T. (Sports Medicine, Upper Extremities, Foot and Ankle, Trauma, Craniomaxillofacial and Thoracic); and Technology & Data, Bone Cement and Surgical. This sales analysis differs from our reportable operating segments, which are based upon our senior management organizational structure and how we allocate resources toward achieving operating profit goals. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.